January 2024 – June 2027
Côte d'Ivoire, Sierra Leone
Despite significant progress in access to ART (Antiretroviral Therapy), the number of deaths related to HIV/AIDS remains well above the set targets. Advanced HIV disease (AHD) (WHO stage 3 or 4 or CD4<200 cells/mm3), associated with a high number of opportunistic infections, is one of the main causes of these deaths. AHD therefore represents a major challenge in the global fight against HIV, particularly in sub-Saharan Africa, where the coverage of recommended interventions is suboptimal due to multifactorial barriers and gaps along the care cascade.
General objective
Prevent deaths in adults and children by simplifying the advanced management of HIVrelated illnesses.
Beneficiaries
-
Some 15 health establishments in Cote d’Ivoire (cohort of around 5,500 PLHIV monitored)
-
11 health establishments in Sierra Leone (cohort of around 12,000 PLHIV monitored)
Results
-
Provide evidence-based data by implementing a decentralized model, rigorous monitoring, and scientific projects
-
Improve the availability of products for AHD, particularly CD4 tests (Managed by MAA). Prepare countries and support their transitions
-
Promote community advocacy and demand generation with a human-centered approach (Managed by MAA)
-
Prepare countries and support their transitions
-
Encourage global advocacy and partner coordination to expand advanced HIV care, combining communication, collaboration, and engagement (Led by Aurum)
